ERAS Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of 10.24%. Erasca, Inc.'s return on equity of -32.03% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Erasca, Inc. has a consensus price target of $10.22, signalling downside risk potential of -2.74%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that Amicus Therapeutics, Inc. has higher upside potential than Erasca, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Erasca, Inc.'s net income of -$30.6M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Immuneering Corp. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -32.03% beat Immuneering Corp.'s return on equity of -78.54%.

Erasca, Inc. has a consensus price target of $10.22, signalling downside risk potential of -2.74%. On the other hand Immuneering Corp. has an analysts' consensus of $16.83 which suggests that it could grow by 263.57%. Given that Immuneering Corp. has higher upside potential than Erasca, Inc., analysts believe Immuneering Corp. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immuneering Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Immuneering Corp. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Immuneering Corp. quarterly revenues of --. Erasca, Inc.'s net income of -$30.6M is lower than Immuneering Corp.'s net income of -$15M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Immuneering Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 323.21x for Immuneering Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -32.03% beat Revolution Medicines, Inc.'s return on equity of -51.27%.

Erasca, Inc. has a consensus price target of $10.22, signalling downside risk potential of -2.74%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $112.53 which suggests that it could grow by 14.59%. Given that Revolution Medicines, Inc. has higher upside potential than Erasca, Inc., analysts believe Revolution Medicines, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.990, suggesting its less volatile than the S&P 500 by 1.046%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Erasca, Inc.'s net income of -$30.6M is higher than Revolution Medicines, Inc.'s net income of -$305.2M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of -40.15%. Erasca, Inc.'s return on equity of -32.03% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Erasca, Inc. has a consensus price target of $10.22, signalling downside risk potential of -2.74%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 75.13%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Erasca, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Erasca, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Erasca, Inc.'s net income of -$30.6M is lower than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 2.15x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.